In one paragraphArticle in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
20 authors.
Fatemeh NosratDepartment of Computational Applied Mathematics and Operations Research, Rice University, Houston, TX, USA.ORCID 0009-0009-2043-7115 Cem DedeDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0543-9325 Lucas B McCullumDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9788-7987 Raul GarciaDepartment of Computational Applied Mathematics and Operations Research, Rice University, Houston, TX, USA.ORCID 0000-0003-1559-6612 Abdallah S R MohamedDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-2064-7613 Jacob G ScottDepartment of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland, OH, USA.ORCID 0000-0003-2971-7673 Brigid A McDonaldDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4230-1330 Kareem A WahidDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0503-0175 Mohamed A NaserDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1020-4966 Renjie HeDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9166-6286 Aysenur KaragozDepartment of Computational Applied Mathematics and Operations Research, Rice University, Houston, TX, USA.
Amy C MorenoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6762-6807 Lisanne V van DijkDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9515-5616 Kristy K BrockDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9364-5040 Jolien HeukelomDepartment of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, Netherlands.ORCID 0000-0001-8042-5401 Seyedmohammadhossein HosseinianEdward P. Fitts Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC, USA.ORCID 0000-0001-7016-5925 Andrew J SchaeferDepartment of Computational Applied Mathematics and Operations Research, Rice University, Houston, TX, USA.ORCID 0000-0002-0379-741X Clifton D FullerDepartment of Computational Applied Mathematics and Operations Research, Rice University, Houston, TX, USA.ORCID 0000-0002-5264-3994 Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3MPaul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0MDevelopment of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac deviceR01DE028290 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTODOULEAS, JOHN PAUL, FULLER, CLIFTON DAVID · 2019 to 2023
$4.3MSCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck CancerR01CA257814 · NCI · RICE UNIVERSITY · PI FULLER, CLIFTON DAVID, SCHAEFER, ANDREW J · 2021 to 2024
$1.8MImage Guided Cancer Therapy Training ProgramT32CA261856 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kristy Brock, Clifton David Fuller · 2022 to 2026
$1.2MProbabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER)R03DE033550 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, NASER, MOHAMED · 2024 to 2025
$499kProvider and Patient-generated Remote Oro-Dental Health Electronic Data Capture for Algorithmic Longitudinal Evaluation and Risk-Assessment (PROHEALER)K01DE030524 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MORENO, AMY CATHERINE · 2022 to 2024
$479kNCI NIH HHS K12 CA088084NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA257814NCI NIH HHS T32 CA261856NIDCR NIH HHS K01 DE030524NIDCR NIH HHS R01 DE028290NIDCR NIH HHS R03 DE033550
6 · The paper itselfAbstract
Background and Purpose: Prior work on adaptive organ-at-risk (OAR)-sparing radiation therapy has typically reported outcomes based on fixed-number or fixed-interval re-planning, which represent one-size-fits-all approaches and do not account for the variable progression of individual patients' toxicities. The purpose of this study was to determine the personalized optimal timing for re-planning in adaptive OAR-sparing radiation therapy, considering limited re-planning resources, for patients with head and neck cancer (HNC). Materials and Methods: A novel Markov decision process (MDP) model was developed to determine optimal timing of re-planning based on the patient's expected toxicity, characterized by normal tissue complication probability (NTCP), for four toxicities. The MDP parameters were derived from a dataset comprising 52 HNC patients treated at the University of Texas MD Anderson Cancer Center between 2007 and 2013. Kernel density estimation was used to smooth the sample distributions. Optimal re-planning strategies were obtained when the permissible number of re-plans throughout the treatment was limited to 1, 2, and 3, respectively. Results: The MDP (optimal) solution recommended re-planning when the difference between planned and actual NTCPs (ΔNTCP) was greater than or equal to 1%, 2%, 2%, and 4% at treatment fractions 10, 15, 20, and 25, respectively, exhibiting a temporally increasing pattern. The ΔNTCP thresholds remained constant across the number of re-planning allowances (1, 2, and 3). Conclusion: In limited-resource settings that impeded high-frequency adaptations, ΔNTCP thresholds obtained from an MDP model could derive optimal timing of re-planning to minimize the likelihood of treatment toxicities.
Indexed as
Markov decision processnormal tissue complication probabilityoptimal strategyorgans at riskPersonalized adaptive radiation therapy
Identifiers
PMID39417124
PMCPMC11482873
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390